Ozempic, Wegovy, associated with rarity of eye disorder, says EMA – National

European Medicines Agency Security Committee The use of drug use in the popular weight loss loss of Novo Nordisk has been completed Aqbay and her Treatment for type 2 diabetes can cause rare cases of a potentially dangerous eye condition.

Non-artery front ischemic optical optical optical neuropathy (Noion) situation called Wegovy and Novo’s diabetes drugs Ozemmet and Rybelsus’s active ingredient 10,000 people, Friday

EMA, which began in December, is due to the approximate increase in the risk of the development of the situation compared to people who do not accept drugs.

Noion is developing in the optical nerve from insufficient blood flow and causes a sudden painless vision in one eye. After the glaucum, the second most common cause of blindness due to optical nerve damage.

1:54
GLP-1 medications such as Ozempic, Wegovy, Alzheimer’s risk for those with diabetes

Research coordinated the semaglutide in the past. However, this was the first time of a regulator.

Get Weekly Health News

Get the latest medical news and health information provided to you every Sunday.

The semaglutide applies to the class of medicines known as the GLP-1 receptor agonists who work by managing blood sugar levels and create a sense of fullness.

A large research of about 350,000 diabetes published earlier this year has shown that more than twelm increases the risk of doubles compared to the long-term semaglutitide compared to medicinal patients.

EMA said it reviewed all information related to the semaglutide, including semaglutide, non-clinical research, clinical trials and post-marketing observation information.

Drammaker recommended to update recipe data for recipe documents for medications, such as side effects such as side effects with “very rare” frequency.

The US Food and Drug Department did not respond immediately to the request of a reuter.